
    
      To assess the long-term effect of the anabolic drug, abaloparatide-subcutaneous (SC) versus
      placebo in the prevention of bone fracture after cessation of treatment. Participants who
      completed the 18-month Double-Blind BA058-05-003 (ACTIVE) study (NCT02653417), after
      receiving abaloparatide-SC or placebo, were enrolled in this extension study to receive 70 mg
      of alendronate (bisphosphonate) weekly for an additional 24 months. Complete details for
      Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417.
    
  